ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,205.47
      0.34%
      US Tech 100
      17,644.80
      0.24%
      Dow Jones
      39,240.93
      0.47%
      Brent Oil
      83.575
      0.02%
      Bitcoin
      61,673.83
      0.79%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. BioXcel Therapeutics Inc (BTAI)

      7. BioXcel Therapeutics Inc (BTAI) News

      BTAI

      BioXcel Therapeutics (BTAI)

      BioXcel Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:BTAI
      DateTimeSourceHeadlineSymbolCompany
      05/09/20249:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
      05/09/20247:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      05/09/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
      04/25/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
      04/24/202410:30AMGlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
      04/22/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
      04/10/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
      03/25/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
      03/15/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
      03/12/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:BTAIBioXcel Therapeutics Inc
      03/01/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
      02/14/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      02/13/20249:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Termination of Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
      02/12/202412:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      02/12/20247:14AMGlobeNewswire Inc.BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)NASDAQ:BTAIBioXcel Therapeutics Inc
      02/08/20245:27PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
      02/08/20244:53PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      02/08/20244:01PMGlobeNewswire Inc.BioXcel Therapeutics Announces Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
      02/08/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      02/06/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®NASDAQ:BTAIBioXcel Therapeutics Inc
      02/05/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
      01/23/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BTAIBioXcel Therapeutics Inc
      01/12/20244:16PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BTAIBioXcel Therapeutics Inc
      12/18/20234:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
      12/18/20234:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
      12/18/20234:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
      12/18/20237:22AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      12/12/20237:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
      12/12/20237:00AMGlobeNewswire Inc.BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day TodayNASDAQ:BTAIBioXcel Therapeutics Inc
      12/11/20237:00AMGlobeNewswire Inc.BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage ProgramsNASDAQ:BTAIBioXcel Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:BTAI